Trial Profile

A phase Ib study evaluating intravenously (IV) administered dexmedetomidine (Dex) for acute treatment of agitation in patients suffering from schizophrenia

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 17 Oct 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

17 Oct 2019 New trial record
03 Jan 2019 According to a BioXcel Therapeutics media release, this study along with a previous study in healthy volunteers(313833 ), as well as agitated patients with Alzheimer's Disease (313750), provides a strong rationale to launch a potential registration trial of BXCL501.
14 Nov 2018 According to a BioXcel Therapeutics, data from this study will guide the company in selecting the optimal dose for BXCL501, a sublingual thin film formulation of Dex, for the acute treatment of agitation.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com